Condition: Chronic Myelogenous Leukemia · Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Sponsor: Novartis Pharmaceuticals
This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| Michigan Med University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Memorial Sloan Kettering | New York, New York, United States | Recruiting |
| Oregon Health Sciences University | Portland, Oregon, United States | Active Not Recruiting |
| Texas Oncology | Dallas, Texas, United States | Recruiting |
| Uni Of TX MD Anderson Cancer Cntr | Houston, Texas, United States | Recruiting |
| Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
| Novartis Investigative Site | CABA, Buenos Aires, Argentina | Recruiting |
| Novartis Investigative Site | Capital Federal, Argentina | Recruiting |
| Novartis Investigative Site | Graz, Austria | Recruiting |
| Novartis Investigative Site | Vienna, Austria | Recruiting |
| Novartis Investigative Site | Rio de Janeiro, Rio de Janeiro, Brazil | Completed |
| Novartis Investigative Site | São Paulo, São Paulo, Brazil | Completed |
+ 73 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04877522